Arrayjet recently installed a customized version of its Ultra Marathon microarrayer instrument at JPT Technologies.
Berlin-based JPT, a subsidiary of BioNTech, will use the Ultra Marathon to print its PepStar peptide microarrays for use in vaccine and immunotherapy development, as well as diagnostics, according to CEO Holger Wenschuh.
Wenshuh said in a statement that the company acquired the high-throughput arrayer, which is capable of printing up to 1,000 slides in a single run, to "comply with large immune monitoring and biomarker discovery projects." He added that the custom instrument meets the "specific challenges of our regulated production environment."
Based in Edinburgh, UK, Arrayjet offers a line of arrayers and services based on its inkjet array printing technology. JPT offers a number of peptide-related services and tools, including high-throughput peptide synthesis and screening, arrays, library assembly, antigen-specific T-cell stimulation, and protein biomarker quantification.
Further details of the deal were not discussed.